Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Fiedler

Internal Medicine Elgin, IL Medical Doctor

NPI 1487623716 CMS profile 248198

745 Fletcher Dr, Suite 101, Elgin, IL 60123

Open in the dashboard

General payments

$6,304

318 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Fiedler of Elgin, IL is reported in the CMS Open Payments database as having received $6,304 across 318 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $161 6
2024 General $695 29
2023 General $1,255 58
2022 General $982 49
2021 General $614 35
2020 General $963 44
2019 General $1,632 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Fiedler
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to John Fiedler were reported at $161. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year John Fiedler Internal Medicine median Middle half National median
2019 $1,632 $159 $48–$570 $163
2020 $963 $119 $33–$402 $114
2021 $614 $135 $37–$521 $132
2022 $982 $141 $42–$496 $149
2023 $1,255 $149 $45–$519 $160
2024 $695 $154 $47–$537 $164
2025 $161 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $1,252 59 payments
  2. Amgen Inc. $679 39 payments
  3. Novo Nordisk Inc $653 35 payments
  4. Janssen Pharmaceuticals, Inc $646 32 payments
  5. AstraZeneca Pharmaceuticals LP $457 29 payments
  6. Amarin Pharma Inc. $363 16 payments
  7. Pfizer Inc. $299 16 payments
  8. AbbVie, Inc. $216 9 payments
  9. Lilly USA, LLC $211 10 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $199 7 payments
  11. Other $1,329 66 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,298 317 payments
  2. Education $6 1 payment
Products named General payments · program years 2019–2025
  1. JARDIANCE $986 46 payments
  2. XARELTO $407 21 payments
  3. Ozempic $405 22 payments
  4. EVENITY $374 23 payments
  5. Prolia $374 23 payments
  6. FARXIGA $312 21 payments
  7. Repatha $281 15 payments
  8. Vascepa $276 12 payments
  9. RYBELSUS $253 11 payments
  10. SPRAVATO $239 11 payments
  11. Other $4,161 207 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 89 drugs

Part D claims

6,773

Median for Internal Medicine: 777

Drug cost

$460,805

Median for Internal Medicine: $73,373

Branded share of claims

14.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 102 $139,891
Eliquis Apixaban Brand 88 $51,394
Xarelto Rivaroxaban Brand 25 $41,093
Januvia Sitagliptin Phosphate Brand 25 $39,053
Farxiga Dapagliflozin Propanediol Brand 13 $23,923
Trulicity Dulaglutide Brand 24 $23,799
Ozempic Semaglutide Brand 14 $17,486
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 29 $17,100
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 17 $10,132
Atorvastatin Calcium Generic 826 $8,903

The 10 drugs with the highest cost, of 89 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$265,322

Of which drugs: $78,973

Medicare patients

376

Average age 77

Services billed

12,317

169 women, 207 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Chronic kidney disease 40%
Diabetes 31%
Ischemic heart disease 24%
Cancer 19%
Osteoporosis 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 31 3,360 $68,272
Vaccine for influenza for injection into muscle 90653 Office 91 91 $7,446
Pcv20 vaccine im 90677 Office 11 11 $3,176

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $77
  • Lilly USA, LLC $32
$109 102 —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $86
$86 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $81
$81 — —
Repatha
  • Amgen Inc. $57
$57 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

318 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record